Overview

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.

Phase:

PHASE2

Details

Lead Sponsor:

University of Cologne

Treatments:

pembrolizumab